Aromatase Inhibitor-Induced Hair Loss in Two Adolescents

The document described two cases of adolescent boys, aged 14 and 16, who developed androgenetic alopecia after treatment with the aromatase inhibitor anastrozole for idiopathic short stature. This side effect had not been previously reported in pediatric patients on aromatase inhibitors. The younger boy exhibited a female Ludwig II pattern of hair loss after 10 months of treatment, while the older boy experienced rapid hair loss progression and was diagnosed with moderate AGA after nearly a year on anastrozole. Both were treated with topical minoxidil, and one also received low-level laser therapy. The paper highlighted that alopecia could be a potential side effect of aromatase inhibitor therapy in adolescents, suggesting that healthcare providers should inform patients about this possibility.